EUVIMEDEUVIMED entdecken
Crossref

Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer

Asia-Pacific Journal of Clinical Oncology · 2026-11 · 22 (S6) · 12-12

DOI: 10.1111/ajco.70227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.11.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer. Asia-Pacific Journal of Clinical Oncology, 22(S6), 12-12. https://doi.org/10.1111/ajco.70227

Vancouver

Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer. Asia-Pacific Journal of Clinical Oncology. 2026;22(S6):12-12. doi:10.1111/ajco.70227

BibTeX
@article{euvimed2026,
  title = {Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  volume = {22},
  number = {S6},
  pages = {12--12},
  doi = {10.1111/ajco.70227}
}
Kostenlos starten →